These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 35872216)
41. The short term safety of COVID-19 vaccines in Australia: AusVaxSafety active surveillance, February - August 2021. Deng L; Glover C; Dymock M; Pillsbury A; Marsh JA; Quinn HE; Leeb A; Cashman P; Snelling TL; Wood N; Macartney K Med J Aust; 2022 Aug; 217(4):195-202. PubMed ID: 35781813 [TBL] [Abstract][Full Text] [Related]
42. Association of Receiving a Fourth Dose of the BNT162b Vaccine With SARS-CoV-2 Infection Among Health Care Workers in Israel. Cohen MJ; Oster Y; Moses AE; Spitzer A; Benenson S; JAMA Netw Open; 2022 Aug; 5(8):e2224657. PubMed ID: 35917125 [TBL] [Abstract][Full Text] [Related]
43. Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers. Angel Y; Spitzer A; Henig O; Saiag E; Sprecher E; Padova H; Ben-Ami R JAMA; 2021 Jun; 325(24):2457-2465. PubMed ID: 33956048 [TBL] [Abstract][Full Text] [Related]
44. [Reasons for allergology consultations prior to COVID-19 vaccination and their outcomes : Two-year experience of an allergy center in North Rhine-Westphalia]. Leonidou Floruß E; Demidova A; Hofmann SC; Balakirski G Dermatologie (Heidelb); 2023 Jul; 74(7):511-519. PubMed ID: 37140637 [TBL] [Abstract][Full Text] [Related]
45. Eyelid edema following the first Pfizer-BioNTech COVID-19 vaccination: is it a coincidence? Baysal Z; Gobeka HH Eur Rev Med Pharmacol Sci; 2022 Jul; 26(14):5264-5267. PubMed ID: 35916826 [TBL] [Abstract][Full Text] [Related]
46. COVID-19 Vaccine Safety in Children Aged 5-11 Years - United States, November 3-December 19, 2021. Hause AM; Baggs J; Marquez P; Myers TR; Gee J; Su JR; Zhang B; Thompson D; Shimabukuro TT; Shay DK MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(5152):1755-1760. PubMed ID: 34968370 [TBL] [Abstract][Full Text] [Related]
47. Interim Recommendations of the Advisory Committee on Immunization Practices for Use of Moderna and Pfizer-BioNTech COVID-19 Vaccines in Children Aged 6 Months-5 Years - United States, June 2022. Fleming-Dutra KE; Wallace M; Moulia DL; Twentyman E; Roper LE; Hall E; Link-Gelles R; Godfrey M; Woodworth KR; Anderson TC; Rubis AB; Shanley E; Jones JM; Morgan RL; Brooks O; Talbot HK; Lee GM; Bell BP; Daley M; Meyer S; Oliver SE MMWR Morb Mortal Wkly Rep; 2022 Jul; 71(26):859-868. PubMed ID: 35771731 [TBL] [Abstract][Full Text] [Related]
48. [Humoral immunity against SARS-CoV-2 in workers of social health care centers of Castilla y León after vaccination with the BNT162b2 mRNA vaccine from Pfizer/Biontech.]. Casas Fischer R Rev Esp Salud Publica; 2021 Oct; 95():. PubMed ID: 34690347 [TBL] [Abstract][Full Text] [Related]
49. The Effectiveness of Pfizer-BioNTech and Oxford-AstraZeneca Vaccines to Prevent Severe COVID-19 in Costa Rica: Nationwide, Ecological Study of Hospitalization Prevalence. Rosero-Bixby L JMIR Public Health Surveill; 2022 May; 8(5):e35054. PubMed ID: 35483079 [TBL] [Abstract][Full Text] [Related]
50. A Cost-Effectiveness Evaluation of Hospitalizations, Fatalities, and Economic Outcomes Associated with Universal Versus Anaphylaxis Risk-Stratified COVID-19 Vaccination Strategies. Shaker M; Abrams EM; Greenhawt M J Allergy Clin Immunol Pract; 2021 Jul; 9(7):2658-2668.e3. PubMed ID: 33711496 [TBL] [Abstract][Full Text] [Related]
51. Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review. Pillay J; Gaudet L; Wingert A; Bialy L; Mackie AS; Paterson DI; Hartling L BMJ; 2022 Jul; 378():e069445. PubMed ID: 35830976 [TBL] [Abstract][Full Text] [Related]
52. Active Surveillance of Adverse Events in Healthcare Workers Recipients After Vaccination with COVID-19 BNT162b2 Vaccine (Pfizer-BioNTech, Comirnaty): A Cross-Sectional Study. Ripabelli G; Tamburro M; Buccieri N; Adesso C; Caggiano V; Cannizzaro F; Di Palma MA; Mantuano G; Montemitro VG; Natale A; Rodio L; Sammarco ML J Community Health; 2022 Apr; 47(2):211-225. PubMed ID: 34628568 [TBL] [Abstract][Full Text] [Related]
53. Evaluation of hematological parameters and thrombocytopenia following Pfizer-BioNTech (BNT162b2) SARS-CoV-2 vaccination. Algaissi A; Alamer E; Jeraiby M; Alomaish A; Elrhima O; Qumayi S; Qasir NA; Areeshi H; Masmali A; Alhazmi A Saudi Med J; 2022 Jun; 43(6):567-571. PubMed ID: 35675927 [TBL] [Abstract][Full Text] [Related]
54. Tolerability of COVID-19 Infection and Messenger RNA Vaccination Among Patients With a History of Kawasaki Disease. Beckley M; Olson AK; Portman MA JAMA Netw Open; 2022 Aug; 5(8):e2226236. PubMed ID: 35960521 [TBL] [Abstract][Full Text] [Related]
55. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers. Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675 [TBL] [Abstract][Full Text] [Related]
56. Assessment of Allergic and Anaphylactic Reactions to mRNA COVID-19 Vaccines With Confirmatory Testing in a US Regional Health System. Warren CM; Snow TT; Lee AS; Shah MM; Heider A; Blomkalns A; Betts B; Buzzanco AS; Gonzalez J; Chinthrajah RS; Do E; Chang I; Dunham D; Lee G; O'Hara R; Park H; Shamji MH; Schilling L; Sindher SB; Sisodiya D; Smith E; Tsai M; Galli SJ; Akdis C; Nadeau KC JAMA Netw Open; 2021 Sep; 4(9):e2125524. PubMed ID: 34533570 [TBL] [Abstract][Full Text] [Related]
57. Are the Allergic Reactions of COVID-19 Vaccines Caused by mRNA Constructs or Nanocarriers? Immunological Insights. Selvaraj G; Kaliamurthi S; Peslherbe GH; Wei DQ Interdiscip Sci; 2021 Jun; 13(2):344-347. PubMed ID: 34021862 [TBL] [Abstract][Full Text] [Related]
58. Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis. Ciampi E; Uribe-San-Martin R; Soler B; García L; Guzman J; Pelayo C; Jürgensen L; Guzman I; Vera F; Galleguillos L; Cárcamo C Mult Scler Relat Disord; 2022 Mar; 59():103690. PubMed ID: 35182880 [TBL] [Abstract][Full Text] [Related]
59. Anaphylaxis to SARS-CoV-2 Vaccines in the Setting of a Nationwide Passive Epidemiological Surveillance Program. Toledo-Salinas C; Scheffler-Mendoza SC; Castano-Jaramillo LM; Ortega-Martell JA; Del Rio-Navarro BE; Santibáñez-Copado AM; Díaz-Ortega JL; Baptista-Rosas R; Sánchez-Novoa P; García-Grimshaw M; Valdés-Ferrer SI; Reyes-Terán G; Mendoza-Hernández DA J Clin Immunol; 2022 Nov; 42(8):1593-1599. PubMed ID: 35976470 [TBL] [Abstract][Full Text] [Related]
60. Polythylene glycol severe allergy and SARS-CoV-2 vaccines: usefulness of testing with PEG 1500 extract. Gaspar A; Moura AL; Cruz C; Borrego LM Eur Ann Allergy Clin Immunol; 2023 Nov; 55(6):261-270. PubMed ID: 36458507 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]